All In Biotech

Drug Trial Radar · NCT07376889

Combination Antibiotic Therapy for Staphylococcus Aureus Bacteremia

COMBAT-SAB: Combination Antibiotic Therapy for Staphylococcus Aureus Bacteremia

Last checked: Nov 19, 2026Latest source record: Sep 25, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 2,096 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

2,096

Planned (sponsor's estimate)

Start

Feb 1, 2026

Primary completion

Jan 2029

Study completion Jan 2029

Sponsor

Lead sponsor
Intermountain Health Care, Inc.Academic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Jan 29, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Crossover
Masking
Single (outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to see if, in selected patients with a serious bacterial infection of the bloodstream, treating the bacterial infection with a combination of antibiotics is more effective than treating the infection with a single antibiotic. Participants must have blood cultures which are positive for a certain type of bacteria.

Conditions

  • Staphylococcus Aureus Bacteremia

Interventions

  • Antibiotic Monotherapy (AM) for patients with methicillin-sensitive S. aureus bacteremia (MSSAB)Drug

    Intravenous anti-staphylococcal beta-lactam, either cefazolin or nafcillin, per the discretion of the treating physician.

  • Antibiotic Monotherapy (AM) for patients with methicillin-resistant S. aureus bacteremia (MRSAB)Drug

    Vancomycin or daptomycin, per discretion of the treating physician

  • Combination Antibiotic Therapy (CAT) for patients with methicillin-sensitive S. aureus bacteremia (MSSAB)Drug

    Patients with methicillin-sensitive S. aureus bacteremia (MSSAB) and no contraindications will receive an anti-staphylococcal beta-lactam, either cefazolin or nafcillin, plus ertapenem

  • Combination Antibiotic Therapy (CAT) for patients with methicillin-resistant S. aureus bacteremia (MRSAB)Drug

    Daptomycin plus ceftaroline

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Desirability of Outcome Ranking (DOOR)Time frame: From enrollment to 30 days post enrollment

Locations

13 sites in 1 country. Site status is shown where the registry gives one.

  • Platte Valley Hospital

    Brighton, Colorado · Recruiting

  • Saint Joseph Hospital

    Denver, Colorado · Recruiting

  • St. Mary's Regional Hospital

    Grand Junction, Colorado · Recruiting

  • Good Samaritan Hospital

    Lafayette, Colorado · Recruiting

  • Lutheran Medical Center

    Wheat Ridge, Colorado · Recruiting

  • St. Vincent Regional Hospital

    Billings, Montana · Recruiting

  • St. James Hospital

    Butte, Montana · Recruiting

  • Holy Rosary Hospital

    Miles City, Montana · Recruiting

  • Intermountain Medical Center

    Murray, Utah · Recruiting

  • McKay-Dee Hospital

    Ogden, Utah · Recruiting

  • Utah Valley Hospital

    Provo, Utah · Recruiting

  • LDS Hospital

    Salt Lake City, Utah · Recruiting

  • St. George Regional Hospital

    St. George, Utah · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.